抗获得性免疫缺陷综合征复方制剂研究进展  

Research progress in anti-AIDS compound preparations

作　　者：孙思曼 江海燕 范潇予 李万芳[2,3] 包捷 王川[1] 靳洪涛 SUN Siman;JIANG Haiyan;FAN Xiaoyu;LI Wanfang;BAO Jie;WANG Chuan;JIN Hongtao(College of Pharmacy,Shaanxi University of Traditional Chinese Medicine,Xianyang Shanxi 712046,China;New Drug Safety Evaluation Center,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Union-Genius Pharmaceutical Technology Development Co.,Ltd.,Beijing 100176,China;NMPA Key Laboratory for Safety Research and Evaluation of Innovative Drug,Beijing 102206,China)

机构地区：[1]陕西中医药大学药学院,陕西咸阳712046 [2]中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京100050 [3]北京协和建昊医药技术开发有限责任公司,北京100176 [4]国家药品监督管理局创新药物安全研究与评价重点实验室,北京102206

出　　处：《中国药物警戒》2024年第9期978-984,共7页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(82074104);中国毒理学会临床毒理学转化研究课题(CST2021CT101)。

摘　　要：目的综述复方制剂在获得性免疫缺陷综合征(AIDS)治疗领域的开发原则及要求,总结抗逆转录病毒疗法(ART)的简化方案,为寻求最佳的药物治疗方案提供参考。方法通过检索国内外相关文献及数据库,对已上市的复方制剂进行整理、分析和归纳。结果目前已上市的抗AIDS复方制剂可以简化ART方案,提高用药依从性,减少药物毒副作用,降低药物负担,提高患者生活质量。结论抗AIDS的复方制剂在治疗方面具有显著优势,但该病的治疗和药物研发仍然存在着重大临床需求,需进一步深入研究。Objective To outline the principles and requirements of developing compound preparations against acquired immunodeficiency syndrome(AIDS),and summarize the simplified regimens of antiretroviral therapy(ART)so as to provide references for seeking the best drug therapy regimens.Methods By searching related domestic and foreign literature and databases,the compound preparations against AIDS on the market were sorted out and analyzed.Results The currently marketed compound preparations against AIDS could simplify ART regimens,enhance medication compliance,reduce drug side effects,lower the drug burden,and improve patients’quality of life.Conclusion Compound preparations against AIDS have significant advantages therapeutically,but there are still significant clinical needs for the treatment of and drug development for this disease,which requires more in-depth research.

关 键 词：人类免疫缺陷病毒 获得性免疫缺陷综合征(艾滋病) 联合用药 复方制剂 药物开发 

分 类 号：R916[医药卫生—药学] R978